Skip to main content
LIFD
OTC Life Sciences

LFTD Partners Reports Massive Q1 Loss, Negative Gross Profit, and $5M+ Impairments Amidst Going Concern Warning and Internal Control Weaknesses

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
10
Price
$0.18
Mkt Cap
$2.668M
52W Low
$0.113
52W High
$1.384
Market data snapshot near publication time

summarizeSummary

LFTD Partners Inc. reported a significantly widened net loss and negative gross profit for Q1 2026, driven by over $5 million in impairments and reserves related to an upcoming hemp ban, while reiterating going concern doubts and disclosing material weaknesses in internal controls.


check_boxKey Events

  • Massive Quarterly Net Loss

    The company reported a net loss of $4.16 million for Q1 2026, a substantial increase from a $0.30 million net loss in Q1 2025.

  • Gross Profit Turns Negative

    Gross profit plummeted to a negative $(1.71) million in Q1 2026, compared to a positive $2.22 million in Q1 2025, primarily due to a significant increase in Cost of Goods Sold.

  • Substantial Impairments and Reserves

    LFTD Partners recorded a $5.06 million inventory reserve (including $4.72 million for hemp-derived products) and a $0.14 million impairment on hemp-specific fixed assets, directly attributable to the national ban on intoxicating hemp-derived products effective November 12, 2026. These amounts are significantly larger than the company's market capitalization.

  • Going Concern Warning Reiterated

    Management expressed 'substantial doubt' about the company's ability to continue as a going concern, citing a history of recurring losses and significant regulatory risks.


auto_awesomeAnalysis

LFTD Partners Inc. reported a catastrophic first quarter, with net losses soaring to $4.16 million from $0.3 million year-over-year, and gross profit turning negative to $(1.71) million. This severe financial deterioration is largely driven by a massive $5.06 million inventory reserve and $0.14 million impairment on hemp-specific fixed assets, directly resulting from the impending national ban on intoxicating hemp-derived products. These impairments alone significantly exceed the company's current market capitalization, highlighting the dire financial state. Management explicitly reiterated 'substantial doubt' about the company's ability to continue as a going concern, a critical red flag for investors. Additionally, the company disclosed material weaknesses in internal controls, including a lack of segregation of duties, and a $350,000 theft of digital currency, further eroding confidence in its operational and financial integrity.

At the time of this filing, LIFD was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.11 to $1.38. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LIFD - Latest Insights

LIFD
May 14, 2026, 5:42 PM EDT
Filing Type: 10-Q
Importance Score:
10
LIFD
Mar 31, 2026, 8:17 PM EDT
Filing Type: 10-K
Importance Score:
9